T&R Biofab Co. Ltd (246710) - Total Liabilities

Latest as of September 2025: ₩72.55 Billion KRW ≈ $49.17 Million USD

Based on the latest financial reports, T&R Biofab Co. Ltd (246710) has total liabilities worth ₩72.55 Billion KRW (≈ $49.17 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore T&R Biofab Co. Ltd equity growth rate to track the company's year-over-year net asset growth rate.

T&R Biofab Co. Ltd - Total Liabilities Trend (2015–2024)

This chart illustrates how T&R Biofab Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See T&R Biofab Co. Ltd (246710) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

T&R Biofab Co. Ltd Competitors by Total Liabilities

The table below lists competitors of T&R Biofab Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
Widepoint C
NYSE MKT:WYY
USA $58.42 Million
ClimateRock Class A Ordinary Shares
NASDAQ:CLRC
USA $9.82 Million
Firetrade Engineering PCL
BK:FTE
Thailand ฿387.68 Million
Seresco S.A.
MC:SCO
Spain €33.81 Million
Shin Shin Co Ltd
TW:2901
Taiwan NT$196.05 Million
Bluecom Co. Ltd
KQ:033560
Korea ₩31.46 Billion
Drb Holding
KO:004840
Korea ₩455.52 Billion
Dreadnought Resources Ltd
AU:DRE
Australia AU$1.22 Million

Liability Composition Analysis (2015–2024)

This chart breaks down T&R Biofab Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 246710 stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.42 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 6.42 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.87 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how T&R Biofab Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for T&R Biofab Co. Ltd (2015–2024)

The table below shows the annual total liabilities of T&R Biofab Co. Ltd from 2015 to 2024.

Year Total Liabilities Change
2024-12-31 ₩74.24 Billion
≈ $50.31 Million
+8.19%
2023-12-31 ₩68.62 Billion
≈ $46.50 Million
+87.10%
2022-12-31 ₩36.67 Billion
≈ $24.85 Million
-9.54%
2021-12-31 ₩40.54 Billion
≈ $27.47 Million
+1552.73%
2020-12-31 ₩2.45 Billion
≈ $1.66 Million
+5.25%
2019-12-31 ₩2.33 Billion
≈ $1.58 Million
+178.40%
2018-12-31 ₩837.09 Million
≈ $567.28K
+111.68%
2017-12-31 ₩395.46 Million
≈ $268.00K
-46.44%
2016-12-31 ₩738.36 Million
≈ $500.38K
-60.60%
2015-12-31 ₩1.87 Billion
≈ $1.27 Million
--

About T&R Biofab Co. Ltd

KQ:246710 Korea Medical Devices
Market Cap
$55.92 Million
₩82.52 Billion KRW
Market Cap Rank
#21419 Global
#1224 in Korea
Share Price
₩2705.00
Change (1 day)
-9.83%
52-Week Range
₩1194.00 - ₩4535.00
All Time High
₩44150.00
About

T&R Biofab Co., Ltd. develops and commercializes various regenerative medical technologies. It offers 3D-printed medical devices; and bio-surgical solutions, which includes wound dressing and acellular dermal matrix, as well as biomaterials and biopharmaceuticals. The company was founded in 2013 and is based in Siheung-si, South Korea.